Cannabidiol (CBD) Treatment for Severe Problem Behaviors in Autistic Boys: A Randomized Clinical Trial.
Doris Trauner, Anya Umlauf, David J Grelotti and 12 others
PMID 40410546WHAT IT FOUND
Purified CBD did not significantly reduce problem behaviors compared to placebo in boys with severe autism.
Both groups improved, with a strong placebo effect observed. Safety was acceptable, but the study found no global benefit over placebo for the primary outcomes.
Key findings
01The primary outcome (RBS-R Total Score) showed a trend toward CBD being better than placebo, but this did not reach statistical significance.
02There was no significant difference between CBD and placebo on the CBCL Total Score, another primary outcome measure.
03Blinded clinicians identified active drug treatment correctly in 68% of children who completed the trial, noting improvements in aggression and communication.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The sample size was modest (39 participants), which may have reduced the power to detect small differences between CBD and placebo. The study included only boys, so findings cannot be generalized to girls with autism. Participants had severe autism with significant functional limitations, which may limit applicability to those with milder symptoms. The primary outcome measures may not have been sensitive enough to detect specific behavioral changes, as suggested by the discrepancy between null statistical results and positive clinician impressions. A strong placebo effect was observed, which may have masked potential benefits of CBD. The trial took place during the pandemic, which may have introduced variability due to school closures and changes in routines.
Declared interests
The study drug (Epidiolex) and placebo were donated by GW Pharmaceuticals. The company had no role in the study design, execution, data collection, analysis, or interpretation.
The easy way to misread this
Do not interpret the positive clinician impressions or the trend in RBS-R scores as evidence that CBD is effective. The primary statistical outcomes were null, meaning the study failed to demonstrate a significant benefit of CBD over placebo for the main behaviors assessed.